GleamWall
中文EN

VRDN Viridian Therapeutics, Inc.\DE

Pharmaceutical Preparations · Nasdaq · SEC CIK 1590750 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-62.8%
TTM net income YoY-50.2%
TTM EPS YoY—
Revenue 3-yr CAGR323.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,781.4%
Net margin-1,724.1%
FCF margin-1,305.4%
EBITDA margin-1,778.7%

Returns

ROE-83.7%
ROA-56.5%
ROIC (approx.)-97.2%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets43.5%
Debt / equity0.00x
Current ratio14.46x
Interest coverage-19.27x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue7.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$70.85M$302,000$314,000$1.77M$2.96M
R&D expense$338.93M$238.25M$159.76M$100.89M$56.89M
SG&A expense$95.31M$61.08M$95.00M$35.18M$25.80M
Operating income-$363.39M-$299.04M-$254.45M-$134.30M-$79.73M
Interest expense$4.95M$2.20M$1.33M$486,000$3,000
Income tax$0————
Net income-$342.60M-$269.95M-$237.73M-$129.87M-$79.41M
EBITDA-$362.94M-$298.50M-$253.93M-$134.05M-$79.61M
EPS (basic)——-5.31-4.05-6.66
EPS (diluted)——-5.31-4.05-6.66
Weighted avg. shares (diluted)——44.76M32.09M11.92M
Balance sheet
Cash & equivalents$212.38M$99.59M$102.83M$155.58M$42.30M
Short-term investments$662.27M$617.99M$374.54M$268.97M$154.67M
Receivables$0————
Inventory$0————
Current assets$894.23M$738.46M$486.48M$431.17M$200.16M
PP&E, net$1.23M$1.24M$1.67M$1.33M$375,000
Intangibles$0————
Total assets$899.42M$742.40M$490.42M$435.09M$203.71M
Current liabilities$70.70M$47.87M$26.64M$33.35M$13.64M
Short-term debt—$0$0——
Long-term debt—$20.58M$20.20M$4.64M$0
Total debt—$20.58M$20.20M$4.64M$0
Total liabilities$177.25M$70.76M$48.40M$40.03M$15.99M
Shareholders' equity$722.17M$671.64M$442.02M$395.06M$187.72M
Net debt—-$79.01M-$82.62M-$150.93M-$42.30M
Shares outstanding101.83M80.99M53.99M41.31M23.92M
Cash flow statement
Operating cash flow-$276.39M-$232.32M-$184.17M-$93.84M-$54.58M
Capital expenditure$495,000$511,000$898,000$797,000$338,000
Free cash flow-$276.89M-$232.83M-$185.07M-$94.64M-$54.92M
Investing cash flow-$37.56M-$228.65M-$94.25M-$115.13M-$74.29M
Financing cash flow$426.74M$457.74M$225.67M$322.24M$125.28M
Depreciation & amortization$460,000$540,000$522,000$255,000$120,000
Stock-based compensation$44.30M$42.15M$67.17M$19.77M$14.46M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.